Known targets — ChEMBL curated mechanism
BRAFFLT1FLT3FLT4KDRKITPDGFRBRAF1RET
The experimentally established mechanism targets of Sorafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 known ✓ | P04049 | 12/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 6/20 | 1.00 |
| ▸ | RET known ✓ | P07949 | 4/20 | 1.00 |
| ▸ | BRAF known ✓ | P15056 | 4/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 2/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 1.00 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 3/20 | 1.00 |
| ▸ | ABL1 | P00519 | 3/20 | 1.00 |
| ▸ | EPHA2 | P29317 | 3/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 3/20 | 1.00 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 3/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sorafenib SCHEMBL8218 | 1.00 | RAF1 (1.00) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL29349634 | 1.00 | RAF1 (1.00) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL28894639 | 0.99 | RAF1 (0.98) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL18863920 | 0.99 | RAF1 (0.98) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL1533981 | 0.99 | RAF1 (0.98) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL1896610 | 0.99 | RAF1 (0.98) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL1533982 | 0.99 | RAF1 (0.98) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL1533976 | 0.99 | RAF1 (0.98) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL28817561 | 0.99 | RAF1 (0.98) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL27786861 | 0.99 | RAF1 (0.98) | RAF1KDRRETBRAFEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023155307-A1 | SORAFENIB OR DONAFENIB ORAL PREPARATION WITH LOW DOSE AND HIGH DRUG EXPOSURE, AND APPLICATION THEREOF | 北京睿创康泰医药研究院有限公司 | 2023-08-24 | — | — | WO | disclosed |
| WO-2023155182-A1 | LOW-DOSE, HIGH-EXPOSURE SORAFENIB OR DONAFENIB ORAL FORMULATION AND USE THEREOF | 北京睿创康泰医药研究院有限公司 | 2023-08-24 | — | — | WO | disclosed |
| US-11078540-B2 | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| US-20190201396-A1 | TREATMENT OF CANCERS HAVING ALTERATIONS WITHIN THE SWI/SNF CHROMATIN REMODELING COMPLEX | THE GENERAL HOSPITAL CORPORATION (US) | 2019-07-04 | — | — | US | disclosed |
| US-20190142830-A1 | C-RAF Mutants that Confer Resistance to RAF Inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-05-16 | — | — | US | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2018049000-A1 | TREATMENT OF CANCERS HAVING ALTERATIONS WITHIN THE SWI/SNF CHROMATIN REMODELING COMPLEX | THE GENERAL HOSPITAL CORPORATION (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20170268069-A1 | Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy | GARRAWAY LEVI A (US) | 2017-09-21 | — | — | US | disclosed |
| CN-105138862-A | Collaborative anti-cancer pharmaceutical combination prediction method and pharmaceutical composition | UNIV TONGJI | 2015-12-09 | — | — | CN | disclosed |
| US-20150141470-A1 | DIAGNOSTIC AND TREATMENT METHODS IN PATIENTS HAVING OR AT RISK OF DEVELOPING RESISTANCE TO CANCER THERAPY | THE BROAD INSTITUTE, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| WO-2015006752-A1 | COMBINATION THERAPIES FOR MALARIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-01-15 | — | — | WO | disclosed |
| WO-2015006753-A2 | THERAPIES FOR DISEASES CAUSED BY ARTHROPOD-BORNE PARASITES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-01-15 | — | — | WO | disclosed |
| WO-2014176700-A1 | BIOSENSORS FOR RAS-DEPENDENT SIGNALING PATHWAYS AND USE THEREOF | Université de Montréal (CA) | 2014-11-06 | — | — | WO | disclosed |
| US-20130059851-A1 | Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141470-A1 | DIAGNOSTIC AND TREATMENT METHODS IN PATIENTS HAVING OR AT RISK OF DEVELOPING RESISTANCE TO CANCER THERAPY | HDAC7, HDAC9, MAPK4 | RAF1 54/4885KDR 3186/4885RET 258/4885 |
| US-20170268069-A1 | Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy | CRKL, RAF1, TPX2 | RAF1 2/4885KDR 1242/4885RET 58/4885 |
| US-11078540-B2 | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy | CRKL, RAF1, TPX2 | RAF1 2/4885KDR 1242/4885RET 58/4885 |
| US-20130059851-A1 | Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy | CRKL, RAF1, TPX2 | RAF1 2/4885KDR 1242/4885RET 58/4885 |
| US-20190142830-A1 | C-RAF Mutants that Confer Resistance to RAF Inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885KDR 752/4885RET 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.